CD279 (PD-1) Monoclonal Antibody (eBioJ105 (J105)), eBioscience™, Invitrogen™

Description

• The J105 MAb reacts with the human PD-1 (programmed death-1), a 55 kDa member of the CD28 immunoglobulin superfamily
• PD-1 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) and plays a key role in peripheral tolerance and autoimmune disease
• PD-1 is expressed predominantly on activated T and B lymphocytes
• Two novel members of the B7 family have been identified as the PD-1 ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC)
• Evidence reported to date suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells
• Costaining experiments suggest that eBioJ105 recognizes a different epitope than MIH4 (cat
• 11-9969)
• Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC)
• T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC
• PD-1 can bind two different but related ligands, PDL-1 and PDL-2
• Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of &quotedanger signals&quote such as LPS or other molecules associated with bacteria or other pathogens
• Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases
• Despite its predicted molecular weight, PD-1 often migrates at higher molecular weight in SDS-PAGE.